GE-21 DRASTIC GENOMIC DIVERGENCE OF RECURRENT MEDULLOBLASTOMA INVALIDATES TARGETED THERAPIES DISCOVERED AT DIAGNOSIS

Recurrence of the childhood brain cancer medulloblastoma is almost universally fatal. The current strategy for clinical trials is to test novel therapies at the time of recurrence, using targets discovered at diagnosis. To define the relationship between naïve and post-treatment medulloblastoma, we...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neuro Oncol
Main Authors: Morrissy, Sorana, Garzia, Livia, Remke, Marc, Ramaswamy, Vijay, Jorgensen, Florence, Wu, Xiaochong, Shah, Sohrab, Ma, Yussanne, Mungall, Karen, Van Meter, Timothy, Cho, Yoon-Jae, Collins, Peter, MacDonald, Tobey, Li, Xiao-Nan, Moore, Richard, Northcott, Paul, Pfister, Stefan, Malkin, David, Marra, Marco, Taylor, Michael
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2014
Assuntos:
Abstracts
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4218185/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nou256.20
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados